Toward a molecular equivalent dose: use of the medaka model in comparative risk assessment.
Recent changes in the risk assessment landscape underscore the need to be able to compare the results of toxicity and dose-response testing between a growing list of animal models and, quite possibly, an array of in vitro screening assays. How do we compare test results for a given compound between vastly different species? For example, what dose level in the ambient water of a small fish model would be equivalent to 10 ppm of a given compound in the rat's drinking water? Where do we begin? To initially address these questions, and in order to compare dose-response tests in a standard rodent model with a fish model, we used the concept of molecular dose. Assays that quantify types of DNA damage that are directly relevant to carcinogenesis integrate the factors such as chemical exposure, uptake, distribution, metabolism, etc. that tend to vary so widely between different phyletic levels. We performed parallel exposures in F344 rats and Japanese medaka (Oryzias latipes) to the alkylating hepatocarcinogen, dimethylnitrosamine (DMN). In both models, we measured the DNA adducts 8-hydroxyguanine, N(7)-methylguanine and O(6)-methylguanine in the liver; mutation frequency using lambda cII transgenic medaka and lambda cII transgenic (Big Blue(R)) rats; and early morphological changes in the livers of both models using histopathology and immunohistochemistry. Pulse dose levels in fish were 0, 10, 25, 50, or 100 ppm DMN in the ambient water for 14 days. Since rats are reported to be especially sensitive to DMN, they received 0, 0.1, 1, 5, 10, or 25 ppm DMN in the drinking water for the same time period. While liver DNA adduct concentrations were similar in magnitude, mutant frequencies in the DMN-exposed medaka were up to 20 times higher than in the Big Blue rats. Future work with other compounds will generate a more complete picture of comparative dose response between different phyletic levels and will help guide risk assessors using "alternative" models.
Hobbie
Kristen R
KR
Comparative Biomedical Sciences Program and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.
Deangelo
Anthony B
AB
King
Leon C
LC
Winn
Richard N
RN
Law
J McHugh
JM
D000818:Animals; D030801:Animals, Genetically Modified; D002273:Carcinogens / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity*; D004247:DNA / Q000235:genetics / Q000302:isolation & purification; D018736:DNA Adducts / Q000032:analysis / Q000378:metabolism; D004128:Dimethylnitrosamine / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D006147:Guanine / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism; D007150:Immunohistochemistry; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D008954:Models, Biological; D009152:Mutagenicity Tests; D009154:Mutation; D009990:Oryzias / Q000235:genetics*; D011897:Random Allocation; D051381:Rats; D011916:Rats, Inbred F344; D055647:Rats, Transgenic; D018570:Risk Assessment; D014881:Water Supply
D002273:Carcinogens; D018736:DNA Adducts; C024829:8-hydroxyguanine; D006147:Guanine; D004247:DNA; C008449:O-(6)-methylguanine; D004128:Dimethylnitrosamine